Fierce Healthcare logo

Coalition of healthcare organizations, experts push forward to improve equity in rare diseases

March 3, 2022 -- Fierce Healthcare featured Eve Dryer, vice president of patient advocacy at Travere Therapeutics, and partners Global Genes and Rare Disease Diversity Coalition in an article about disparities in rare disease care.

Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and the rare community worldwide in recognizing today as Rare Disease Day 2022.

Read the full press release >

Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2021 financial results and provided a corporate update.

Read the full press release >

Creating a Better Future for Families Affected by Rare Disease

February 7, 2022 -- With many of our team members impacted by rare disease themselves – our mission at Travere is personal. Read about what inspires our team’s determination to bring life-changing treatment, support and hope to people living with rare disease in this story in Fortune.
PharmaVoice Logo

For the CEO of Travere, running a rare disease company is personal

February 3, 2022 -- This week, PharmaVOICE featured a Q&A with our president and CEO Eric Dube on what it takes to succeed in rare disease. The key takeaway? The people within the company, the science, a patient-inspired culture, humility – and a true passion for making a difference. Read the article >
Life Sciences Voice Top Industry Leaders 2021 logo

In the News: Our president and CEO Eric Dube named Top Industry Leader by Life Sciences Voice

January 27, 2022 -- Eric Dube, president and CEO of Travere Therapeutics, was named a Top Industry Leader for 2021 by Life Sciences Voice. The magazine honored 50 distinguished individuals for this award. Read the article >


Sean talks about his family and their journey with Alagille syndrome. Alagille syndrome, or ALGS, is a rare genetic disorder that can affect the liver, heart, skeleton, eyes and kidneys. For Sean's family, ALGS impacts each affected child differently. For more information and support, contact the Alagille Syndrome Alliance at

Travere Therapeutics Provides Corporate Update and 2022 Outlook

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2021 to be approximately $55 million.

Read the full press release >
Jula Inrig M.D.

Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement.

Read the full press release >
Newborn Screening

Landmark Study Calls for Modernization of Newborn Screening System in US

Rare families face too many challenges with our current newborn screening system in America. In partnership with patient advocates, Travere has been championing change at the federal and state level to catalyze advancements for patients.